Impact of COVID-19 on the Latin American population in Spain during the first and second waves

Bengelloun, Adrián K.; Ortega, Guillermo J.; Soriano, Joan B.

doi:10.1016/j.medcle.2021.04.012

Cited by 1 publication

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, they were on average, older, required a longer hospitalization and had worse clinical outcomes in all assessments (all p <0.05), likely related with the medical decision to type their blood group. Further, there were more persons of Latin-American origin (p<0.05), confirming our earlier publication (Table 1) [24].…”

Section: Resultssupporting

confidence: 90%

“…Within this research, comorbidities were not identified as independent drivers in our null association with ABO blood group. However, in our previous research comorbidities were found to be major drivers of health outcomes in COVID-9 and Long COVID, and we identified that both number of and specific comorbidities, such as obesity, previous chronic respiratory disease or cardiovascular disease [23,24].…”

Section: Implications For the Futurementioning

confidence: 75%

“…We obtained information from clinical records of all adult patients (age � 18 years) with a positive COVID-19 clinical diagnosis upon hospital admission, confirmed either by positive antigen or polymerase chain reaction (PCR) tests. Further details about this cohort are available elsewhere [23,24]. The research protocol was approved (CEIm 10/21 with N˚4.468).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

ABO blood group as a determinant of COVID-19 and Long COVID: An observational, longitudinal, large study

Soriano,

Peláez,

Busquets

et al. 2023

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background An association of ABO blood group and COVID-19 remains controversial. Methods Following STROBE guidance for observational research, we explored the distribution of ABO blood group in patients hospitalized for acute COVID-19 and in those with Long COVID. Contingency tables were made and risk factors were explored using crude and adjusted Mantle-Haentzel odds ratios (OR and 95% CI). Results Up to September 2022, there were a total of 5,832 acute COVID-19 hospitalizations in our hospital, corresponding to 5,503 individual patients, of whom blood group determination was available for 1,513 (27.5%). Their distribution by ABO was: 653 (43.2%) group 0, 690 (45.6%) A, 113 (7.5%) B, and 57 (3.8%) AB, which corresponds to the expected frequencies in the general population. In parallel, of 676 patients with Long COVID, blood group determination was available for 135 (20.0%). Their distribution was: 60 (44.4%) from group 0, 61 (45.2%) A, 9 (6.7%) B, and 5 (3.7%) AB. The distribution of the ABO system of Long COVID patients did not show significant differences with respect to that of the total group (p ≥ 0.843). In a multivariate analysis adjusting for age, sex, ethnicity, and severity of acute COVID-19 infection, subgroups A, AB, and B were not significantly associated with developing Long COVID with an OR of 1.015 [0.669–1.541], 1.327 [0.490–3.594] and 0.965 [0.453–2.058], respectively. The effect of the Rh+ factor was also not significant 1,423 [0.772–2,622] regarding Long COVID. Conclusions No association of any ABO blood subgroup with COVID-19 or developing Long COVID was identified.